Index

A
Acute kidney injury (AKI) 147–148
biomarker analysis, 147–148
in cardiopulmonary bypass surgery patients, 144
patient population, 145–147
post-operative prediction, 152
pre-operative predictors, 151–154
pro-inflammatory biomarkers, 144
risk assessment tools, 144
risk score, 144
sample collection, 147
statistical analysis, 148–151
uTi, 144, 145

Adipokine markers, 194, 199–200
Adiponectin receptor C-terminal fragment
(AdipoR/AipoR CTF) 65–66
animal models, 97–98
antibodies, 98
bioassays, 95
biomarker measurements, 98
blood sample preparation, 80
brain morphologic observations, 87
cell and tissue staining procedure, 86
cell culture methods, 95, 99
cell culture treatment, 95–96, 99
cell lines, 95
cell proliferation counts, 97
cellular insulin, 97, 100–102
conjugates and standards, 66–67
correlation to inflammation, 118, 119
diabetic collection, 116
disease progression, 98, 102, 104–106
ELISA, 96

blood levels, 74
calibrator reproducibility and stability, 72
cross reactivity, 72
immunoglobulin bound form measurement, 67–68
immunoglobulin chain identification, 71
interference testing, 73
patient recovery, 73
fat morphologic observations, 86
fatty-acid oxidation, 62, 63
FBG measurement, 112
gestational diabetes collection, 114–115
Ig-CTF correlations, 119, 121
Ig-CTF distribution, 118, 120
predictive values, Ig-CTF, 120, 122
gluconeogenesis, 62, 63
glucose clamp, 113
G protein-coupled receptor, 63–64
HbA1c measurement, 112
IDE, 78–79
Ig-CTF and CTF measurements, 116
Ig-CTF R1 values, sample measurement, 116–118
iMALDI approach, 68–69
immunoglobulin binding mechanism, 70–71
immunfluorescent staining, 87–89
inhibition studies
ADAM17/TACE and IDE activity, 81–84
InnoZyme™ Insulysin-IDE
Immunocapture Activity Assay Kit, 80
InnoZyme™ TACE Activity Kit, 80
insulin

© Springer International Publishing Switzerland 2015
M. Pugia (ed.), Inflammatory Pathways in Diabetes: Biomarkers and Clinical Correlates, Progress in Inflammation Research,
DOI 10.1007/978-3-319-21927-1
Adiponectin receptor C-terminal fragment (AdipoR/AipoR CTF) (cont.)
receptor response, 88, 90
sensitivity/resistance, 112, 113
sensitizing agent, 62
intracellular calcium, 96–97, 99–100
in-vivo insulin, 101–103, 105–106
leptin resistance, 94
liver morphologic observations, 87
mass spectroscopy peptide enrichment assays, 71–72
mechanism of action, 104, 107
MEROPS search, 78
muscle
  glucose uptake, 62, 63
  morphologic observations, 86
OGTT, 112
oligomeric isoforms, 62
pancreas morphologic observations, 87
patient reproducibility and stability, 73
peptide preparation, 64–65
plasma forms, 85
precision and accuracy testing, 73
pre-diabetic
  collection, 115, 116
  correlation, 121–123
  protease identification, 79–80
  reference range testing, 114
  SELDI-MALDI method, 69
  SISCAPA method, 68
  TACE, 79
  T-cadherin, 63
tissue
  and blood analysis, 81
  forms and distribution, 85
  sample preparation, 80
TNF-α, 62
TZD treatment, 62
western blot method, 67, 70, 96, 98–99
western blot techniques, 81
X-ray crystallography analysis, 62
Adipose stress markers, 201–203
Advanced glycation end products (AGEs), 195–196
  vs. CD59 markers, 6
  glycated hemoglobin, 5
  human serum albumin, 5
  molecular damages, 5
  nontraditional markers, 5
  receptors activation, 5–6
AGEs See Advanced glycation end products (AGEs)
Aprotinin, 172, 183–185

B
β-secretase (BACE), 78–79
Biacore testing, 65
Bikunin (Bik)
  anti-inflammatory cellular signaling
  aprotinin, 183–185
  Ca²⁺ in-flux, 179, 186
  cellular signal response, 177–179
  DPP-4, 178–181
  membrane disruption, 179, 180, 185–186
  necrosis, 185
  peptide analogs, 181–183
  PI3K-Akt pathway, 181, 182, 186–187
  proliferation, 186
  proteinuria, 184
  trypsin inhibition, 182, 184
  urinary trypsin inhibitor, 172
Bioassays, 95

C
Cardiomyocyte (C2C12) models
  cell culture treatment, 99
  intracellular calcium, 99–100
  western blot analysis, 98–99
Cardiovascular disease (CVD), 18, 38–39
  adiponectin response, 168
  atherosclerosis, 157
  demographic characteristics, 161, 162, 164
  diagnostic risk factor, 161, 163, 164
  epidemiological evidence, 158
  indicators, 157–158
  PAR activation, 158–159
  statistics methods, 161
CD59 glycoprotein
  animal experimental model, 41
  glycated (see Glycated CD59 (GCD59))
  glycation-inactivation, 39–40, 42–43
MAC inhibition mechanism, 35–36
Chronic kidney disease (CKD), 131, 137, 139
Complement system
  diabetic complications
    cardiovascular disease, 38–39
    nephropathy, 36–37
    neuropathy, 38
    retinopathy, 37
MAC
  alternative pathway, 31, 33
  classical pathway, 31, 33
  inhibitory protein (see CD59 glycoprotein)
MBL/lectin pathway, 31, 33
non-lytic effects, 34–35
therapeutic application, 44
C-reactive protein (CRP)
acute phase reactants, 158
pro-inflammatory response, 166, 168
vascular stenosis, inflammation markers, 164–166
C-terminal fragment (CTF) See Adiponectin receptor C-terminal fragment (AdipoR/AipoR CTF)
CVD See Cardiovascular disease (CVD)

D
Dysfunctional cell growth markers
AdipoR1 CTF, 206
Akt-PI3K pathway, 206
hypoxia, 204–206

E
ELISA See Enzyme linked immunosorbent assays (ELISA)
Endothelial dysfunction
adipose angiotensin, 12
Bikunin, 13
chronic activation, 12
kinin formation, 11–12
nitric oxide, 11
TFPI action, 13
Endothelial stress markers, 203–204
Enzyme linked immunosorbent assays (ELISA), 96, 174
blood levels, 74
calibrator reproducibility and stability, 72
cross reactivity, 72
immunoglobulin bound form measurement, 67–68
immunoglobulin chain identification, 71
interference testing, 73
patient recovery, 73

F
Fasting blood glucose (FBG), 112
Fatty acid markers, 200–201
Fibrosis
Bikunin action, 17
coaulation, 16
mechanism, 16, 17
PAR activation, 15–16
Free fatty acids (FFAs), 9–10

G
GCD59 See Glycated CD59 (GCD59)
Gestational diabetes
collection, 114–115
Ig-CTF correlations, 119, 121
Ig-CTF distribution, 118, 120
predictive values, Ig-CTF, 120, 122
Glomerular filtration rate (GFR), 129, 131, 132
Glycated CD59 (GCD59)
ELISA, 46
HbA1c assay, 45
OGTT test, 47
plasma level, 46–47

H
Hyperglycemia
complications with, 3
glycation stress (see Advanced glycation end products (AGEs))
insulin resistance, 3–4
oxidative stress, 6–7
stress markers
AGE, 195–196
glycation stress markers, 195
impaired insulin metabolism, 194–195
insulin resistance, 193–195
stress factor, 193, 194
therapeutic approaches, 196

I
Inflammation
endothelial dysfunction
adipose angiotensin, 12
Bikunin, 13
chronic activation, 12
kinin formation, 11–12
nitric oxide, 11
TFPI action, 13
fibrosis
Bikunin action, 17
coaulation, 16
mechanism, 16, 17
PAR activation, 15–16
innate immune apoptosis
complement system, 15
cytokines, 14–15
lymphocytes, 14–15
mechanism, 13–14
serine proteases, 15
T-cells, 15
Infliximab, 114
Innate immune mediated apoptosis
   complement system, 15
cytokines, 14–15
lymphocytes, 14–15
mechanism, 13–14
ersine proteases, 15
T-cells, 15
Innate immunity markers, 206–207
Insulin-degrading enzyme (IDE), 78–79
Insulin resistance, 3–4

M
Membrane attack complex (MAC)
   alternative pathway, 31, 33
classical pathway, 31, 33
inhibitory protein (see CD59 glycoprotein)
MBL/lectin pathway, 31, 33
non-lytic effects, 34–35
MEROPS search, 78
Metabolic syndrome (MetSyn), 166, 167
Modified Eagle Medium (MEM), 95–96

N
Nephropathy, 18–19, 36–37
Neuropathy, 20, 38

O
Obesity, 194, 198–199
   adipose signaling
      adiponectin, 8
ghrelin level, 8–9
hypoxia, 10
leptin signals, 7
free fatty acids, 9–10
inflammatory response (see Inflammation)
   prevalence, U.S., 3–4
Oral glucose tolerance test (OGTT), 112
Oxidative stress markers, 197
   biomarker measurements, 196–197
   ROS, 196, 198

P
Protease activate receptors (PAR) signalling,
   15–16

R
Reactive oxidative species, 196–198
Reactive oxygen species (ROS), 6–7
Retinopathy, 19, 37
ROS See Reactive oxidative species; Reactive oxygen species (ROS)

T
Thiazolidinediones (TZD) treatment, 62
TNF-α–converting enzyme (TACE), 79

U
Urinary trypsin inhibitor (uTi), 144, 145
   anti-inflammatory cellular signaling
      Akt and PIK3 measurements, 175
      apoptosis assays, 176
      cell culturing procedure, 173–174
      DPP-4 peptidase activity assay, 174
      intra-cellular analysis, 176
      proliferation, 181, 186
      protease and inhibitor balance, 177, 178
      serine protease activity, 174
      trypsin-specific chromogenic substrate,
         176–177
      western-blot analysis, 175
CRP
   acute phase reactants, 158
   pro-inflammatory response, 166, 168
   vascular stenosis, inflammation
   markers, 164–166
CVD
   adiponectin response, 168
   atherosclerosis, 157
   demographic characteristics, 161, 162, 164
   diagnostic risk factor, 161, 163, 164
   epidemiological evidence, 158
   indicators, 157–158
   PAR activation, 158–159
   statistics methods, 161
Kunitz type inhibitor, 172
   marker analysis, 160–161
   metabolic syndrome (MetSyn), 166, 167
   patient assessment, 159–160
   sample collection, 160–161
   uristatin immunoassay
      anti-inflammatory response, 127–131, 139
      clinical analysis, 133–134
      cross-reactivity, 132
      dipstick method, 132
      follow-up care, 137–138
      health screen collection, 134–135
      hospital infection collection, 136
hospital patient collection, 136
kidney model, 128–131
proteinuria/hematuria, 138–139
sample and data bank, 134–135
urinary tract infection collection, 136
urine samples, 137
viral infections, 138
WBC, 129–132
Western blot, 136–137
uristatin response, 168
Uristatin (Uri) immunoassay
anti-inflammatory response, 127–131, 139
clinical analysis, 133–134
cross-reactivity, 132
dipstick method, 132
follow-up, 137–138
health screen collection, 134–135
hospital infection collection, 136
hospital patient collection, 136
kidney model, 128–131
proteinuria/hematuria, 138–139
sample and data bank, 134–135
urinary tract infection collection, 136
urine samples, 137
viral infections, 138
WBC (see White blood cells (WBCs))
western blot, 136–137
uTi See Urinary trypsin inhibitor (uTi)

W
White blood cells (WBCs)
anti-inflammatory response, 129–130
cell death, 131–132
neutrophilic elastase, 129